EMulate Therapeutics Announces Publication of Positive Preclinical Data Assessing Pain Reduction via Low and Ultra-Low Radiofrequency Energy Delivery

Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.

BELLEVUE, Wash., Oct. 18, 2022 (GLOBE NEWSWIRE) — EMulate Therapeutics, a clinical-stage digital therapy company specializing in the life sciences developing safe, non-invasive and highly effective treatments for cancers and other serious diseases, today announced the release of positive preclinical data evaluating the use of its lightweight, portable device that uses proprietary WAV files to deliver specific low to ultra low radio frequency energy (ulRFE®) in validated mouse models of pain. The results demonstrate a statistically significant reduction in visceral, neuropathic and inflammatory pain in these models. The data was published in Electromagnetic Biology and Medicine and accessible here.

The use of magnetic fields to affect biological processes in living systems has been well studied over the past decades. Using electromagnetic fields like ulHowever, EFR to achieve therapeutic results is a more recent development. Successful pain reduction through the application of ulERF has the potential to solve common problems with current pharmacological standards of care, perhaps the most important of which is the potential to ulRFE to provide a consistent effect to the exposed region, thereby overcoming enzyme, blood-brain and other barriers to drug delivery to affected parts of the biological system, as well as the effects of drug administration, systemic dilution and clearance who are experienced with traditionally administered drugs.

“We are delighted that the results of our latest study are published and we are encouraged by the positive results. The information we gained from this study will inform the design of our future preclinical studies and enable our clinical studies as we continue to explore the untapped potential of our ulRFE technology in reducing pain and other disease indications,” said Chris Rivera, CEO of EMulate Therapeutics.

“We are encouraged by the results of this study which show that our radio frequency energy WAV files consistently and specifically produced statistically significant effects in the pain models tested, in some cases with a greater effect than the pain medications. reference used to validate each model,” said Xavier. Figueroa, Ph.D. Principal Scientist for EMulate Therapeutics. “These results suggest that the magnetic fields produced by our WAV files, and particularly those with frequencies below 10 kHz, can provide effective reduction in pain sensation in these pain studies.”

About EMulate Therapeutics, Inc.

EMulate Therapeutics is a clinical-stage company that uses its proprietary radio frequency energy (RFE) technology targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to provide safe and effective therapeutic benefits specifically targeted to patients’ underlying conditions. The company has generated encouraging human data on patients with glioblastoma and diffuse midline glioma and is preparing for pivotal studies (phase III) in each indication. It has also generated encouraging preclinical studies in pain management and mental health models and is preparing for the first human clinical trials in each area. In addition, positive data has been generated independently in the field of animal health (positive results for cancer in more than 20 different types of solid tumors in dogs (pets)), as well as in bio- agriculture. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial-stage consumer wellness wearable technology company spun off from EMulate in 2019. EMulate is Hapbee’s largest independent shareholder and receives quarterly royalties on net sales.

About our ulRFE device

EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered portable investigational medical device that uses low to ultra-low level frequencies (DC-22kHz) to deliver specific electromagnetic frequencies. signals to reduce pain sensations. The system emits a low power magnetic field (

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements”. Forward-looking statements address matters that are not historical facts. Because they address future events or conditions, forward-looking statements may include words such as “anticipate”, “believe”, “estimate”, “intend”, “could”, “should”, “could”, “could”, “seek”, “plan”, “could”, “will”, “expect”, “anticipate”, “predict”, “project”, “plan”, “potential” and “continue” or their negative forms or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future, and are not guarantees of future performance. Although we believe that these assumptions and expectations are reasonable and made in good faith, the assumed facts or bases almost always differ from the actual results, and the differences between the assumed facts or expectations and the actual results could be material, depending on the circumstances. Where, in a forward-looking statement, our management expresses an expectation or belief regarding future results, such expectation or belief is expressed in good faith and is believed to have a reasonable basis. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from the results of operations or the plans expressed or implied by these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

We cannot predict all of the risks and uncertainties that could affect our business, financial condition or results of operations. Accordingly, the forward-looking statements contained in this press release should not be taken as representations that the results or conditions described in such statements will occur or that our goals and plans will be achieved. These forward-looking statements can be found at various places in this press release and may include information regarding possible or projected future results of our operations, including statements about potential acquisition or merger targets, strategies or plans; business strategies; prospects; future cash flows; financing plans; management plans and objectives; any other statements regarding future acquisitions, future cash requirements, future operations, business plans and future financial results; and any other statements that are not historical facts.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, change of events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Contact Investor

David Matteson

Tel (425) 478-2121

[email protected]

Media Contact

Michael Tattory

LifeSci Communications

Tel (646) 751-4362

[email protected]